,Canonical_Smiles,drug_name,drug_type,Label
0,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,S_mephenytoin_4_hydroxylase-Substrate,positive
1,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
2,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,Tazarotene,S_mephenytoin_4_hydroxylase-Substrate,positive
3,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
4,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
5,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
6,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
7,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
8,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,Sildenafil,2E1-Inhibitor,negative
9,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
10,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,Timoprazole,-,negative
11,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
12,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
13,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
14,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,S_mephenytoin_4_hydroxylase-Substrate,positive
15,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
16,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
17,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,SUL-Substrate,negative
18,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
19,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer,negative
20,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfadimidine,-,negative
21,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
22,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
23,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
24,CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,NO_1886,2C8-Substrate,negative
25,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
26,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
27,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
28,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
29,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,Ebastine,-,negative
30,CC(C)c1cccc(C(C)C)c1O,Propofol,S_mephenytoin_4_hydroxylase-Substrate,positive
31,C1CNCCN1,Piperazine,2D6-Substrate,negative
32,Cc1cccc(Nc2ccccc2C(=O)O)c1C,Mefenamic Acid,S_mephenytoin_4_hydroxylase-Substrate,positive
33,NCCc1ccc(O)c(O)c1,Dopamine,19A-Inhibitor,negative
34,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
35,CCN(CC)C(=O)c1cccc(C)c1,Diethyltoluamide,2E1-Substrate,negative
36,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
37,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
38,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,Amoxapine,2D6-Substrate,negative
39,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,2D6-Substrate,negative
40,CCn1nnc(C2=CCCN(C)C2)n1,LU_2509,2D6-Substrate,negative
41,c1ccc(C2(c3ccccc3)C[C@H]2C2=NCCN2)cc1,Cibenzoline,2D6-Substrate,negative
42,Cc1ccsc1-c1ccc([C@H](C)C(=O)O)cc1,S_MTPPA,2C9-Substrate,negative
43,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
44,Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@@H]5C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@@H]3C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]2C)c(N)c1=O,Dactinomycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
45,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,CP2CI-Inhibitor,negative
46,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
47,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
48,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
49,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
50,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
51,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1c1cccc([N+](=O)[O-])c1,Nitrendipine,P450_HFLA-Substrate,negative
52,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,Proadifen,-,negative
53,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
54,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
55,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
56,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,Sulfasalazine,-,negative
57,C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor,negative
58,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2D6-Inhibitor,negative
59,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,P450_HFLA-Substrate,negative
60,CN[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@@H]3N)[C@@H]2O)OC[C@]1(C)O,Gentamicin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
61,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
62,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
63,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
64,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
65,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,Methyltransferase-Inhibitor,negative
66,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
67,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
68,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,Benzbromarone,-,negative
69,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer,negative
70,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,Vardenafil,HLp2-Substrate,negative
71,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Gefitinib,2D6-Inhibitor,negative
72,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
73,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
74,C/C=C\C,cis_2_butene,2E1-Substrate,negative
75,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
76,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
77,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
78,CCOc1ccc2ccc(=O)oc2c1,7_ethoxy_coumarin,2E1-Substrate,negative
79,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
80,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
81,CNC(=O)Oc1cccc2ccccc12,carbaryl,2E1-Substrate,negative
82,COc1ccc2[nH]cc(CCN(C(C)C)C(C)C)c2c1,foxy,2D6-Substrate,negative
83,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
84,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
85,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
86,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,negative
87,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,Cinacalcet,2D6-Substrate,negative
88,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
89,CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,Dalfopristin,-,negative
90,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
91,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
92,COc1ccc2c(c1)c(CC(=O)NCC(O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,2_hydroxy_indomethacin_phenethylamide,2D6-Substrate,negative
93,Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,Clofenotane,19A-Inhibitor,negative
94,C=CC#N,acrylonitrile,2E1-Substrate,negative
95,CCCCCCCC/C=C\CCCCCCCC(=O)O,oleic_acid,2E1-Substrate,negative
96,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
97,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
98,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
99,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,Naloxone,S_mephenytoin_4_hydroxylase-Substrate,positive
100,O[C@@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,Nebivolol,2D6-Substrate,negative
101,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
102,C#CC1(O)C=CC2C3CCC4=CC(=O)CCC4C3CCC21CC,Gestodene,-,negative
103,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
104,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
105,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
106,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,S_mephenytoin_4_hydroxylase-Substrate,positive
107,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Roquinimex,-,negative
108,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
109,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
110,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
111,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
112,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
113,NC[C@H](O)c1ccc(O)cc1,Octopamine,2D6-Substrate,negative
114,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
115,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
116,CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],Pyridostigmine bromide,-,negative
117,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
118,Oc1ncnc2[nH]ncc12,Allopurinol,2E1-Inhibitor,negative
119,Cc1c2ccccc2c(C)c2c1ccc1ccccc12,DMBA,2E1-Substrate,negative
120,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2CC[C@@H]1N2C,Cocaine,GST-Inducer,negative
121,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
122,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer,negative
123,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
124,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor,negative
125,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
126,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,S_mephenytoin_4_hydroxylase-Substrate,positive
127,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Perphenazine,S_mephenytoin_4_hydroxylase-Substrate,positive
128,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
129,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
130,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,Benzethonium,2D6-Substrate,negative
131,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
132,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,Tecastemizole,-,negative
133,CN1C(=O)[C@H](O)N=C(c2ccccc2)c2cc(Cl)ccc21,Temazepam,S_mephenytoin_4_hydroxylase-Substrate,positive
134,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,Perospirone,2D6-Substrate,negative
135,C[C@@H](CN1c2ccccc2Sc2ccccc21)N(C)C,Promethazine,2D6-Inhibitor,negative
136,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
137,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
138,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
139,CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,Etretinate,19A-Inhibitor,negative
140,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
141,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
142,CCN[C@@H](C)Cc1ccccc1,Etilamfetamine,2D6-Substrate,negative
143,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
144,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
145,CN1C(CC(=O)c2ccccc2)CCCC1CC(O)c1ccccc1,Lobeline,-,negative
146,COCCc1ccc(OC[C@H](O)CNC(C)C)cc1,Metoprolol,2D6-Substrate,negative
147,CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1,Ketobemidone,S_mephenytoin_4_hydroxylase-Substrate,positive
148,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
149,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
150,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
151,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
152,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
153,Cc1ncsc1CCCl,Clomethiazole,2E1-Inhibitor,negative
154,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
155,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,Mebendazole,-,negative
156,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,negative
157,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,Trazodone,P450_HFLA-Substrate,negative
158,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
159,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
160,COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,Silymarin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
161,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
162,CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1,diuron,2E1-Substrate,negative
163,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
164,CCOc1ccc2nc3ccc(=O)cc-3oc2c1,7_ethoxy_resorufin,1A2-Substrate,negative
165,C=Cc1ccccc1,styrene,2E1-Substrate,negative
166,CCCC(=O)O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate,negative
167,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
168,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Methylprednisolone Aceponate,3A4-Inducer,negative
169,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
170,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
171,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
172,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,Almotriptan,2D6-Substrate,negative
173,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,negative
174,c1ccc2[nH]ccc2c1,indole,2E1-Substrate,negative
175,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
176,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
177,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
178,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
179,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,Teriparatide,24A-Inhibitor,negative
180,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
181,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
182,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
183,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor,negative
184,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
185,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
186,COc1ccc2c3c1OC1C(O)C=CC4C(C2)NCCC341,Norcodeine,2D6-Substrate,negative
187,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
188,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
189,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
190,CN1C(=O)OC(C)(C)C1=O,Trimethadione,S_mephenytoin_4_hydroxylase-Substrate,positive
191,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
192,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
193,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
194,CCCCN(CCCC)CC[C@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,Halofantrine,S_mephenytoin_4_hydroxylase-Substrate,positive
195,COc1ccc(CCNCCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_R,2C8-Substrate,negative
196,C[n+]1c2cc(N)ccc2cc2ccc(N)cc21.Cl.Nc1ccc2cc3ccc(N)cc3nc2c1.[Cl-],Acriflavinium Chloride,1B1-Inducer,negative
197,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O,tamarixetin,2C9-Substrate,negative
198,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
199,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
200,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,testosterone,2C19-Substrate,negative
201,CCCCN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C,bupivacaine_R,2D6-Substrate,negative
202,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
203,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
204,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen_R,2C9-Substrate,negative
205,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
206,Nc1ccccc1,Aniline,-,negative
207,COCc1c(C(C)C)nc(C(C)C)c(C=C[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,Cerivastatin,S_mephenytoin_4_hydroxylase-Substrate,positive
208,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)C(=NOCC(=O)O)c3csc(N)n3)[C@H]2SC1,Cefixime,Solute_carrier_family_15_member_1-Substrate,negative
209,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
210,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,cp_122_721,2D6-Substrate,negative
211,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
212,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
213,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
214,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
215,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1,Bisoprolol,2D6-Substrate,negative
216,CCCN1CCCC2Cc3nc(N)ncc3CC21,Quinelorane,-,negative
217,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,Delavirdine,2D6-Inhibitor,negative
218,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
219,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
220,Clc1ccccc1CN1CCc2sccc2C1,Ticlopidine,2E1-Inhibitor,negative
221,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Testosterone,S_mephenytoin_4_hydroxylase-Substrate,positive
222,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
223,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Pimozide,2E1-Inhibitor,negative
224,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
225,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
226,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,Vincamine,2E1-Substrate,negative
227,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,S_mephenytoin_4_hydroxylase-Substrate,positive
228,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Cetirizine,-,negative
